Citations (86)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Dirk Schriefer, Rocco Haase, Nils-Henning Ness & Tjalf Ziemssen. (2022) Cost of illness in multiple sclerosis by disease characteristics – A review of reviews. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 177-195.
Read now
Read now
Carrie M. Hersh, Richard A. Brook, Ian A. Beren, Nicholas J. Rohrbacker, Lori Lebson, Christian Henke & Amy L. Phillips. (2021) The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis. Journal of Medical Economics 24:1, pages 479-486.
Read now
Read now
Francesco Patti, María Luisa Martínez Ginés, Christiane Norenberg & Fernando Duarte Caron. (2020) BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT®. Patient Preference and Adherence 14, pages 771-779.
Read now
Read now
Mitzi J. Williams, Kristen Johnson, Helen M. Trenz, Stephanie Korrer, Rachel Halpern, Yujin Park & Vivian Herrera. (2018) Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate. Current Medical Research and Opinion 34:1, pages 107-115.
Read now
Read now
Andrea Zimmer, Michael Coslovsky, Ivo Abraham & Bernhard F Décard. (2017) Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study. Patient Preference and Adherence 11, pages 1815-1830.
Read now
Read now
Dessalegn Y Melesse, Ruth Ann Marrie, James F Blanchard, Bo Nancy Yu & Charity Evans. (2017) Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort. Patient Preference and Adherence 11, pages 1093-1101.
Read now
Read now
María Dolores Edo Solsona, Emilio Monte Boquet, Bonaventura Casanova Estruch & José Luis Poveda Andrés. (2017) Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis. Patient Preference and Adherence 11, pages 415-421.
Read now
Read now
Peter Joseph Jongen, Wim A Lemmens, Raymond Hupperts, Erwin LJ Hoogervorst, Hans M Schrijver, Astrid Slettenaar, Els L de Schryver, Jan Boringa, Esther van Noort & Rogier Donders. (2016) Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines. Patient Preference and Adherence 10, pages 909-917.
Read now
Read now
Damiano Paolicelli, Eleonora Cocco, Valentina Di Lecce, Vita Direnzo, Lucia Moiola, Roberta Lanzillo, Paola Perini, Simona Malucchi, Giovanna Borriello, Emilio Portaccio, Valentina Panetta, Giuseppe Fenu, Francesca Sangalli, Laura Cacciaguerra & Maria Trojano. (2016) Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opinion on Drug Delivery 13:6, pages 799-805.
Read now
Read now
Nina Parikh Thomas, Suellen Curkendall, Amanda M. Farr, Elaine Yu & Dana Hurley. (2016) The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis. Journal of Medical Economics 19:5, pages 497-505.
Read now
Read now
Antonios Bayas & Mathias Mäurer. (2015) Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence. Patient Preference and Adherence 9, pages 265-274.
Read now
Read now
Ewa Stawowczyk, Krzysztof Piotr Malinowski, Paweł Kawalec & Paweł Moćko. (2015) The indirect costs of multiple sclerosis: systematic review and meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research 15:5, pages 759-786.
Read now
Read now
C. M. Kozma, D. M. Meletiche & A. L. Phillips. (2015) The effect of age and sex on cost of inpatient facility encounters among patients with multiple sclerosis. Journal of Medical Economics 18:9, pages 704-710.
Read now
Read now
Sander Yermakov, Matthew Davis, Michaela Calnan, Monica Fay, Brieana Cox-Buckley, Sujata Sarda, Mei Sheng Duh & Ravi Iyer. (2015) Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. Journal of Medical Economics 18:9, pages 711-720.
Read now
Read now
Antonios Bayas, Jean Christophe Ouallet, Boris Kallmann, Raymond Hupperts, Ulrich Fulda & Kurt Marhardt. (2015) Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opinion on Drug Delivery 12:8, pages 1239-1250.
Read now
Read now
Luis Lizán, Marta Comellas, Silvia Paz, José Luis Poveda, Dennis M Meletiche & Carlos Polanco. (2014) Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature. Patient Preference and Adherence 8, pages 1653-1664.
Read now
Read now
Volker Limmroth & Kathrin Gerbershagen. (2014) Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a. Expert Opinion on Drug Delivery 11:12, pages 1969-1978.
Read now
Read now
Niklas Bergvall, Allison A. Petrilla, Swapna U. Karkare, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan, Gorana Capkun, Charles Makin, Catherine Balderston McGuiness & Jonathan R. Korn. (2014) Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Journal of Medical Economics 17:10, pages 696-707.
Read now
Read now
Chris M Kozma, Michael Dickson, Amy L Phillips & Dennis M Meletiche. (2013) Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Preference and Adherence 7, pages 509-516.
Read now
Read now
Maureen J. Lage, Cathryn A. Carroll & Kathleen A. Fairman. (2013) Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment. Journal of Medical Economics 16:9, pages 1146-1153.
Read now
Read now
Gabriel Adelman, Stanley G. Rane & Kathleen F. Villa. (2013) The cost burden of multiple sclerosis in the United States: a systematic review of the literature. Journal of Medical Economics 16:5, pages 639-647.
Read now
Read now
Articles from other publishers (65)
Marion SchaufHarini ChinthapatlaSeema DimriEdward LiDaniel M. Hartung. (2023) Economic burden of multiple sclerosis in the United States: A systematic literature review. Journal of Managed Care & Specialty Pharmacy 29:12, pages 1354-1368.
Crossref
Crossref
Laura Maria Beatrice Belotti, Mirko Di Martino, Corrado Zenesini, Luca Vignatelli, Elisa Baldin, Flavia Baccari, Ben Ridley & Francesco Nonino. (2023) Impact of adherence to disease-modifying drugs in multiple sclerosis: A study on Italian real-world data. Multiple Sclerosis and Related Disorders 80, pages 105094.
Crossref
Crossref
Raed Al-Roughani, Magd Zakaria, Edward J. Cupler & Karim Taha. (2023) Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study. Frontiers in Neurology 14.
Crossref
Crossref
James John Marriott, Okechukwu Ekuma, Randall Fransoo & Ruth Ann Marrie. (2023) Switching to second line MS disease-modifying therapies is associated with decreased relapse rate. Frontiers in Neurology 14.
Crossref
Crossref
Aliza Bitton Ben-Zacharia, Bryan Walker, Amy Perrin Ross, Carlo Tornatore, Natalie C. Edwards, Yvette Lipman & Amy L. Phillips. (2023) Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review. International Journal of MS Care 25:5, pages 188-195.
Crossref
Crossref
Lilyana Amezcua, Terrie Livingston, Brooke Hayward, Jia Zhou & Mitzi J. Williams. (2023) Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world data. Multiple Sclerosis and Related Disorders 77, pages 104866.
Crossref
Crossref
Zuber Khan, Ghanshyam Das Gupta & Sidharth Mehan. (2023) Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges. Journal of Clinical Medicine 12:13, pages 4274.
Crossref
Crossref
Barry Hendin, Richard Brook, Ian Beren, Nathan Kleinman, Cindy Fink, Amy Phillips & Carroline Lobo. (2023) The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity. Journal of Health Economics and Outcomes Research, pages 91-101.
Crossref
Crossref
Barry Hendin, Richard A. Brook, Ian A. Beren, Nathan Kleinman, Cindy Fink, Amy L. Phillips & Carroline Lobo. (2023) The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity. Journal of Health Economics and Outcomes Research 10:1.
Crossref
Crossref
Maha S Al-Keilani & Basima A Almomani. (2023) Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study. International Journal of Pharmacy Practice 31:2, pages 198-205.
Crossref
Crossref
Lita Araujo, Svend S. Geertsen, Allen Amedume, Keiko Higuchi & Janneke van Wingerden. (2022) Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study. Neurology and Therapy 11:4, pages 1735-1748.
Crossref
Crossref
Amanda M. Kibbons, Ryan Moore, Leena Choi, Megan Peter & Autumn D. Zuckerman. (2022) Individual and Community-Level Characteristics and Adherence to Specialty Medications. Journal of Pharmacy Practice, pages 089719002211319.
Crossref
Crossref
Volker Limmroth, Kirsten Bayer-Gersmann, Christian Mueller & Markus Schürks. (2022) Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study. JMIR Formative Research 6:3, pages e31972.
Crossref
Crossref
Daniel M. Hartung, Kirbee A. JohnstonJessina C. McGregorDennis N. Bourdette. (2022) Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare Population. International Journal of MS Care 24:2, pages 90-97.
Crossref
Crossref
Aleksandra Kołtuniuk & Justyna Chojdak-Łukasiewicz. (2022) Adherence to Therapy in Patients with Multiple Sclerosis—Review. International Journal of Environmental Research and Public Health 19:4, pages 2203.
Crossref
Crossref
Daniel M. Hartung, Kirbee A. JohnstonJessina C. McGregor & Dennis N. Bourdette. (2022) Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D Program. Neurology Clinical Practice 12:1, pages 36-42.
Crossref
Crossref
Christian P. Kamm, Praveen Manjakunnel, Dirk Lehnick, Martin Welter, Andrew Chan, Nicole Kamber & Tim Vanbellingen. (2022) From Diagnosis to Satisfaction in Multiple Sclerosis: A Swiss Patient Survey Highlighting the Importance of the First Diagnostic Consultation. Clinical and Translational Neuroscience 6:1, pages 4.
Crossref
Crossref
Adam BurkhardJoshua ToliverKaren Rascati. (2021) Association between multiple sclerosis disease severity and adherence to disease-modifying therapies. Journal of Managed Care & Specialty Pharmacy 27:7, pages 915-923.
Crossref
Crossref
Daniel M. Hartung. (2021) Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA. Current Neurology and Neuroscience Reports 21:7.
Crossref
Crossref
Emanuele D’Amico, Aurora Zanghì, Marzia Romeo, Eleonora Cocco, Giorgia Teresa Maniscalco, Vincenzo Brescia Morra, Damiano Paolicelli, Giovanna De Luca, Simonetta Galgani, Maria Pia Amato, Giuseppe Salemi, Matilde Inglese, Paolo Agostino Confalonieri, Giacomo Lus, Carlo Avolio, Antonio Gallo, Marika Vianello, Marco Onofrj, Massimo Filippi, Maria Trojano & Francesco Patti. (2021) Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics 18:2, pages 905-919.
Crossref
Crossref
Eugene Y. Chan. (2021) Moral foundations underlying behavioral compliance during the COVID-19 pandemic. Personality and Individual Differences 171, pages 110463.
Crossref
Crossref
Machaon Bonafede, Rina Mehta, Gilwan Kim, Ila Sruti, Marc Tian, Corey Pelletier & Neil Goldfarb. (2020) Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis. PharmacoEconomics - Open 5:1, pages 23-34.
Crossref
Crossref
Wolfgang Köhler, Kirsten Bayer-Gersmann, Thomas Neußer, Markus Schürks & Tjalf Ziemssen. (2021) Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT® Autoinjector: A Prospective Observational Cohort Study. Frontiers in Neurology 12.
Crossref
Crossref
N. Poudel, B. Banjara, S. Kamau, N. Frost & S. Ngorsuraches. (2021) Factors influencing patients’ willingness-to-pay for disease-modifying therapies for multiple sclerosis. Multiple Sclerosis and Related Disorders 48, pages 102720.
Crossref
Crossref
Nam-Eun Kim, Sanghun Lee, Bo Yeon Kim, Ae Gi Hwang, Ji Hyeon Shin, Hyeon-Jong Yang & Sungho Won. (2021) The nationwide retrospective cohort study by Health Insurance Review and Assessment Service proves that asthma management decreases the exacerbation risk of asthma. Scientific Reports 11:1.
Crossref
Crossref
Daniel M. Hartung. (2021) Health economics of disease-modifying therapy for multiple sclerosis in the United States. Therapeutic Advances in Neurological Disorders 14, pages 175628642098703.
Crossref
Crossref
Meheroz H Rabadi, Kimberly Just & Chao Xu. (2021) The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis. Journal of Central Nervous System Disease 13, pages 117957352110287.
Crossref
Crossref
Jacqueline Nicholas, Huanxue Zhou & Chinmay Deshpande. (2020) Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis. Advances in Therapy.
Crossref
Crossref
Ingrid E. H. Kremer, Mickael Hiligsmann, Josh Carlson, Marita Zimmermann, Peter J. Jongen, Silvia M. A. A. Evers, Svenja Petersohn, Xavier G. L. V. Pouwels & Nick Bansback. (2020) Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. Medical Decision Making 40:8, pages 1003-1019.
Crossref
Crossref
Daniel M. Hartung, Kirbee A. Johnston, Jessina C. McGregor & Dennis N. Bourdette. (2020) The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis. Multiple Sclerosis and Related Disorders 46, pages 102554.
Crossref
Crossref
Mary Filipi & Samantha Jack. (2020) Interferons in the Treatment of Multiple Sclerosis. International Journal of MS Care 22:4, pages 165-172.
Crossref
Crossref
Daniel Golan, Smadar Sagiv, Lea Glass-Marmor & Ariel Miller. (2020) Mobile phone-based e-diary for assessment and enhancement of medications adherence among patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical 6:3, pages 205521732093930.
Crossref
Crossref
Antonio Marangi, Gabriele Farina, Virginia Vicenzi, Stefano Forlivesi, Francesca Calabria, Fabio Marchioretto, Antonio Forgione, Francesca Rossi, Gianola Stenta, Marika Vianello, Alberto Gajofatto & Maria Donata Benedetti. (2020) Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy. Multiple Sclerosis and Related Disorders 41, pages 102004.
Crossref
Crossref
Gary Cutter, Antonella Veneziano, Augusto Grinspan, Mahir Al-Banna, Alexey Boyko, Maria Zakharova, Eva Maida, Marija Bosnjak Pasic, Sanjay K. Gandhi, Robin Everts, Cinzia Cordioli & Silvia Rossi. (2020) Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD. Multiple Sclerosis and Related Disorders 40, pages 101957.
Crossref
Crossref
Chungyi Chiu, Malachy Bishop, Bradley McDaniels, Byung-Jin Kim & Lebogang Tiro. (2018) A Population-Based Investigation of Health-Care Needs and Preferences in American Adults With Multiple Sclerosis. Journal of Patient Experience 7:1, pages 34-41.
Crossref
Crossref
Natasha Frost, Jerome Freeman, Diana Brixner, Jane Mort, James Clem & Surachat Ngorsuraches. (2019) Patients’ preferences and willingness-to-pay for disease-modifying therapies. Multiple Sclerosis and Related Disorders 35, pages 55-60.
Crossref
Crossref
Volker Limmroth, Klaus Hechenbichler, Christian Müller & Markus Schürks. (2019) Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp). Journal of Medical Internet Research 21:7, pages e14373.
Crossref
Crossref
Daniel M. HartungKirbee A. JohnstonAdriane IrwinSheila MarkwardtDennis N. Bourdette. (2019) Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D. Health Affairs 38:2, pages 303-312.
Crossref
Crossref
Volker Limmroth, Iason Bartzokis, Eckhard Bonmann, Patrick Kusel, Thomas Schreiner & Markus Schürks. (2018) The BETACONNECT™ system: MS therapy goes digital. Neurodegenerative Disease Management 8:6, pages 399-410.
Crossref
Crossref
Andrew V. Thach, Carolyn M. Brown, Vivian Herrera, Rahul Sasane, Jamie C. Barner, Kentya C. Ford & Kenneth A. Lawson. (2018) Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis. International Journal of MS Care 20:6, pages 251-259.
Crossref
Crossref
Stanley Cohan, Kyle Smoot, Kiren Kresa-Reahl, Robert Garland, Wei-Shi Yeh, Ning Wu & Crystal Watson. (2018) Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study. Advances in Therapy 35:11, pages 1894-1904.
Crossref
Crossref
Kristina F Simacek, John J Ko, Debbie Moreton, Stefan Varga, Kristen Johnson & Bozena J Katic. (2018) The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study. Journal of Medical Internet Research 20:10, pages e11168.
Crossref
Crossref
Marti GroenewegSara H. ForresterBeth ArnoldLorella PalazzoWeiwei ZhuPaul YoonTim Scearce. (2018) One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program. Journal of Managed Care & Specialty Pharmacy 24:5, pages 458-463.
Crossref
Crossref
Daniel Kantor, Kristen Johnson, Maria Cecilia Vieira, James Signorovitch, Nanxin Li, Wei Gao, Valerie Koo, Emilie Duchesneau & Vivian Herrera. (2018) Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis. Journal of the Neurological Sciences 388, pages 168-174.
Crossref
Crossref
James John Marriott, Hui Chen, Randall Fransoo & Ruth Ann Marrie. (2018) Validation of an algorithm to detect severe MS relapses in administrative health databases. Multiple Sclerosis and Related Disorders 19, pages 134-139.
Crossref
Crossref
Diego Centonze, Sergio Iannazzo, Laura Santoni, Cecilia Saleri, Elisa Puma, Luigi Giuliani & Pier Luigi Canonico. (2017) The economic profile of peginterferon beta-1a in the treatment of relapsing-remitting multiple sclerosis in Italy. Multiple Sclerosis and Demyelinating Disorders 2:1.
Crossref
Crossref
Ingo Kleiter, Michael Lang, Judith Jeske, Christiane Norenberg, Barbara Stollfuß & Markus Schürks. (2017) Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study. BMC Neurology 17:1.
Crossref
Crossref
Michael Munsell, Molly Frean, Joseph Menzin & Amy L. Phillips. (2017) Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs. BMC Neurology 17:1.
Crossref
Crossref
Brittany Gerber, Tara Cowling, Guanmin Chen, Michael Yeung, Pierre Duquette & Paola Haddad. (2017) The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: Real world evidence from Alberta, Canada. Multiple Sclerosis and Related Disorders 18, pages 218-224.
Crossref
Crossref
Daniel M. Hartung. (2017) Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA. Neurotherapeutics 14:4, pages 1018-1026.
Crossref
Crossref
Kristen M. JohnsonHuanxue ZhouFeng LinJohn J. KoVivian Herrera. (2017) Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. Journal of Managed Care & Specialty Pharmacy 23:8, pages 844-852.
Crossref
Crossref
Charity Evans, Ruth Ann Marrie, Feng Zhu, Stella Leung, Xinya Lu, Elaine Kingwell, Yinshan Zhao & Helen Tremlett. (2017) Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations. Pharmacoepidemiology and Drug Safety 26:6, pages 702-711.
Crossref
Crossref
Peter Joseph Jongen, Wim A. Lemmens, Erwin L. Hoogervorst & Rogier Donders. (2017) Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study). Health and Quality of Life Outcomes 15:1.
Crossref
Crossref
Kyla A. McKay, Charity Evans, John D. Fisk, Scott B. Patten, Kirsten Fiest, Ruth Ann Marrie & Helen Tremlett. (2017) Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. Neuroepidemiology 48:3-4, pages 124-130.
Crossref
Crossref
Stephen J. Tueller, Pascal R. Deboeck & Richard A. Van Dorn. (2016) Getting less of what you want: reductions in statistical power and increased bias when categorizing medication adherence data. Journal of Behavioral Medicine 39:6, pages 969-980.
Crossref
Crossref
Uwe Klaus Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Jörg Czekalla, Klaus Hechenbichler, Volker Limmroth & Michael Hecker. (2016) Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary. Advances in Therapy 33:5, pages 834-847.
Crossref
Crossref
Zaza Katsarava, Birgit Ehlken, Volker Limmroth, Kirsi Taipale, Sarita Noemi Patel, Gabriele Niemczyk, Karin Rehberg-Weber & Colin Wernsdörfer. (2015) Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program. BMC Neurology 15:1.
Crossref
Crossref
Anja Fischer, Marcus Fischer, Robert A. Nicholls, Stephanie Lau, Jana Poettgen, Kostas Patas, Christoph Heesen & Stefan M. Gold. (2015) Diagnostic accuracy for major depression in multiple sclerosis using self‐report questionnaires. Brain and Behavior 5:9.
Crossref
Crossref
Cathryn A Carroll, Kathleen A Fairman & Maureen J Lage. (2014) Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data. BMC Health Services Research 14:1.
Crossref
Crossref
Raymond Hupperts, Lizette Ghazi-Visser, Ana Martins Silva, Michalis Arvanitis, Hanna Kuusisto, Kurt Marhardt & Nikolaos Vlaikidis. (2014) The STAR Study: A Real-World, International, Observational Study of the Safety and Tolerability of, and Adherence to, Serum-Free Subcutaneous Interferon β-1a in Patients With Relapsing Multiple Sclerosis. Clinical Therapeutics 36:12, pages 1946-1957.
Crossref
Crossref
Ching-Piao Tsai, Feng-Cheng Lin & Charles Tzu-Chi Lee. (2014) Beta2-adrenergic agonist use and the risk of multiple sclerosis: a total population-based case-control study. Multiple Sclerosis Journal 20:12, pages 1593-1601.
Crossref
Crossref
Jonathan D. Campbell, Vahram Ghushchyan, R. Brett McQueen, Sharon Cahoon-Metzger, Terrie Livingston, Timothy Vollmer, John Corboy, Augusto Miravalle, Teri Schreiner, Victoria Porter & Kavita Nair. (2014) Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Multiple Sclerosis and Related Disorders 3:2, pages 227-236.
Crossref
Crossref
Uwe K Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Klaus Hechenbichler & Volker Limmroth. (2013) Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study. BMC Neurology 13:1.
Crossref
Crossref
Ana Ožura, Lea Kovač & Saša Šega. (2013) Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis. Clinical Neurology and Neurosurgery 115, pages S6-S11.
Crossref
Crossref
Ching-Piao Tsai & Charles Tzu-Chi Lee. (2013) Impact of Disease-Modifying Therapies on the Survival of Patients with Multiple Sclerosis in Taiwan, 1997–2008. Clinical Drug Investigation 33:9, pages 647-652.
Crossref
Crossref